SEC Form 4 · accession 0002139479-26-000004
Candel Therapeutics, Inc. · CADL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark E. Sims
Officer — Chief Commercial Officer
Period of report
Jul 6, 2026
Accepted (ET)
Jul 8, 2026 · 4:12 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001841387
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $10.03 | Jul 6, 2026 | A | 285,000 | A | — | Jul 6, 2036 | Common Stock | 285,000 | 285,000 | D |
Explanation of responses
- F125% of the shares underlying this option shall vest and become exercisable on July 6, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.